Abstract 9342: DNA Methylation Biomarkers Capture Residual Biological Risk Beyond Traditional Clinical Predictors
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.9342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Diensn G Xing und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Clinical risk models rely on traditional risk factors that may not fully capture relevant biology. DNA methylation (DNAm)-based biomarkers have been shown to predict mortality better than chronological age. In this study, we investigate if DNAm adds predictive utility to clinical models and quantifies residual biological risk that is not captured by clinical predictors. Hypothesis: We hypothesized that a DNAm-derived mortality score would remain independently associated with all-cause mortality, provide independent risk information, and improve discrimination beyond PREVENT-like clinical predictors.
Methods
We analyzed NHANES 1999-2002 participants with DNAm epigenetic biomarkers and linked CDC mortality files. A DNAmScore was derived from epigenetic clocks and DNAm mortality biomarkers using elastic-net Cox regularization with repeated nested cross-validation for tuning. We compared three models: DNAmScore alone, a PREVENT-like clinical model (age, sex, BMI, systolic blood pressure, total cholesterol, HDL cholesterol, eGFR, diabetes, smoking, antihypertensive medication, and lipid-lowering medication), and the combined model. Cross-fitted out-of-fold discrimination was assessed using inverse probability of censoring-weighted time-dependent ROC/AUC at 10 and 15 years. Adjusted hazard ratios were estimated using a weighted complete-case Cox model.
Results
In the cross-fitted ROC cohort ( n =3,767), 1,018 and 1,580 deaths occurred by 10 and 15 years, respectively. In the weighted adjusted Cox model, DNAmScore remained strongly associated with all-cause mortality after clinical adjustment (HR=2.27 per 1 SD; 95% CI, 1.90-2.70; p
Zitieren
APA
Xing, D. G., Bhuiyan, M. S., Modi, K. A., Conrad, S., Rom, O., Orr, W., & Bhuiyan, M. (2026). Abstract 9342: DNA Methylation Biomarkers Capture Residual Biological Risk Beyond Traditional Clinical Predictors. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.9342
Vancouver
Xing DG, Bhuiyan MS, Modi KA, Conrad S, Rom O, Orr W, et al. Abstract 9342: DNA Methylation Biomarkers Capture Residual Biological Risk Beyond Traditional Clinical Predictors. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.9342
BibTeX
@article{Xing2026,
author = {Xing, Diensn G and Bhuiyan, Md Shenuarin and Modi, Kalgi A and Conrad, Steven and Rom, Oren and Orr, Wayne and Bhuiyan, Mohammad},
title = {Abstract 9342: DNA Methylation Biomarkers Capture Residual Biological Risk Beyond Traditional Clinical Predictors},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.9342}
}
EUVIMED